The Global Atopic Dermatitis Market Is Expected To Grow At A CAGR Of 8.2% During The Forecast Period 2017-2023.

Atopic dermatitis affects a large percentage of the world's population. The skin of a patient with atopic dermatitis becomes dry, red, flaky and very itchy. Although atopic dermatitis can occur at any age, but mostly it affects infants and young children. Occasionally, it may persist in adults as well. Some patients tend to have a protracted course with ups and downs. Mostly, there are periods of time when the disease gets worse, known as exacerbations or flares, which is followed by periods when the skin improves or clears up entirely, called remissions.

Increasing prevalence of skin irritants such as soaps, detergents, perfumes, cosmetics and even water may produce inflammation that may cause the skin to become inflamed. Additionally rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development and rapidly developing technology is expected to fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth during the period 2017-2023.

The global atopic dermatitis market is expected to grow at a CAGR of 8.2 % during the forecast period 2017-2023.

Get a sample report at https://www.marketresearchfuture.com/sample_request/1610 .

The Americas dominate the global atopic dermatitis market owing to the presence of huge patient with skin diseases and infectious disorders, such as staphylococcal and streptococcal bacterial skin infections. Furthermore high healthcare spending, and increasing government support for research & development fuel the market growth.

Europe holds the second largest share of the global atopic dermatitis market as result of increasing focus of various government agencies on the treatment of allergic diseases. Moreover, the growing public awareness about atopic dermatitis is likely to boost the European market.

Asia Pacific is the fastest growing atopic dermatitis market across the globe. Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development is projected to drive the market in China and India over the forecasted period.

The Middle East and Africa holds the least share of the global market due to limited funds, ignorance of diseases, and poor access to treatment.

Segmentation

The global atopic dermatitis market is segmented on the basis of types, by application, and by end user. On the basis of the type, it is segmented into hormone, Erythropoietin, Monoclonal antibodies, Interferon, Calcitonin, and others. On the basis of the application, it is segmented into cancer, blood disorders, chronic diseases, infectious diseases, and others. On the basis of end user, it is segmented into hospitals, clinics, and research centers.

Browse Complete Report at https://www.marketresearchfuture.com/reports/atopic-dermatitis-market-1610 .

Some of key the players in the market are Astellas Pharma Inc. (Japan), Sanofi S.A. (France), Regeneron Pharmaceuticals, Inc. (U.S.), Valeant Pharmaceuticals International, Inc (Canada), Anacor Pharmaceuticals Inc. (U.S.), Novartis International AG (Switzerland), Bristol-Myers Squibb (U.S.), Meda Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Galderma S.A. (Switzerland), Allergan Plc. (Republic of Ireland)

Atopic dermatitis have various patterns depending on the age of patients. It can occur in the knees, inside the elbows, sides of the neck, wrists, ankles, and hands and has the tendency to develop papules which leads to rashes. It is characterized by low quantity of filaggrin protein that allows skin to become dry and reduces its protective abilities. Additionally, the skin is very susceptible to infections, such as staphylococcal and streptococcal bacterial skin infections, warts, herpes simplex, and molluscum contagiosum. The atopic dermatitis market growth is majorly attributed to the increasing prevalence of atopic disorders, decreased quantity of protein called filaggrin in skin. Moreover, rising funding along with government support for research and development fuel the market of atopic dermatitis. Moreover, advancing technology in medical devices is adding fuel to the growth of the market.

According to a report published by the National Center for Biotechnology Information, in 2015, atopic dermatitis was recorded to affect around 20% of infants & children and 3% of adults globally

A research study published in the National Eczema Association, in 2016, shows that around 9.6 million children under the age of 18years, which is 13% of U.S. population, have atopic dermatitis. Additionally, in 2016, the United States spend around $314 million on health system to treat atopic dermatitis patients.

About us
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future
P: +1 646 845 9312
W: www.marketresearchfuture.com
sales@marketresearchfuture.com

This release was published on openPR.